Ganesh Rajaraman

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 147 citations · Full text

Discovery of <i>N</i>-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

Keith F. McDaniel, Le Wang, Todd Soltwedel et al. · Journal of Medicinal Chemistry · 2017 · 133 citations · Full text

Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain

George S. Sheppard, Le Wang, Steven D. Fidanze et al. · Journal of Medicinal Chemistry · 2020 · 116 citations · Full text

Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors

Le Wang, John K. Pratt, Todd Soltwedel et al. · Journal of Medicinal Chemistry · 2017 · 64 citations · Full text

Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats

Guqi Wang, Hong Shen, Ganesh Rajaraman et al. · European Journal of Pharmacology · 2007 · 47 citations

Liver Fatty Acid, Metabolic Syndrome, Antioxidant Function +13